|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical and microbiological characterization of Clostridium difficile infection in a tertiary care hospital in Shanghai, China显示文摘 | Dong Danfeng Peng Yibing Zhang Lihua Jiang Cen Wang Xuefeng Mao Enqiang | 2014 | Chinese Medical Journal2014，，9： | 3 |
| 2 | Low molecular weight heparin reduces arterial blood lactic acid content and increases estimated glomerular filtration rate in patients with moderate Covid-19 pneumonia显示文摘Background:Coronavirus disease 2019(Covid-19)remains a serious health threat worldwide.We aimed to investigate whether low molecular weight heparin(LMWH)can promote organ function recovery in moderate Covid-19 pneumonia patients.Methods:We initiated an LMWH protocol in Covid-19 patients with increased D-dimer,body mass index>30 kg/m^(2) or a history of diabetes from January 18,2020 at Shanghai Public Health Clinical Center.In this retrospective study,we assigned moderate Covid-19 pneumonia patients admitted between January 18th and April 18,2020 receiving the LMWH protocol to the LMWH group.Moderate patients who met the inclusion criteria but did not receive LMWH protocol were included in the control group by 1:2 propensity score matching.General clinical information,indicators for renal function,arterial blood gas analyses,arterial blood lactic acid content(mmol/L),and coagulation indexes at 0 day,3 days,7 days,and 11 days after admission were recorded and compared between the two groups.Results:There were 41 patients in the LMWH group and 82 patients in the control group.General information in both groups were similar.Compared to the control group,the arterial blood lactic acid content(mmol/L)at day 11(1.3[1.1,1.7]vs.1.2[0.9,1.3],P=0.016)was reduced in the LMWH group.The estimated glomerular filtration rate(eGFR)in the LMWH group was higher than that in the control group at day 7(108.54[89.11,128.17]vs.116.85[103.39,133.47],P=0.039)and day 11(113.74[94.49,126.34]vs.128.31[112.75,144.12],P=0.003).The serum creatinine levels(Scr)in the LMWH group were lower than that in the control group at day 7(62.13[51.47,77.64]vs.55.49[49.50,65.75],P=0.038)and day 11(63.35[50.17,75.73]vs.51.62[44.62,61.24],P=0.005).Conclusions:LMWH treatment can reduce arterial blood lactic acid levels and improve eGFR in moderate Covid-19 pneumonia patients.Randomized controlled trials are warranted to further investigate this issue. | Li Ma Yigang Zeng Bing ZhaoL ili Xu Jian Li Tongyu Zhu Enqiang Mao | 2022 | Chinese Medical Journal2022，，6： | 3 |
| 3 | 96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients显示文摘Background and Aims:Tenofovir amibufenamide(TMF)is a novel phosphoramidated prodrug of tenofovir with nonin-ferior efficacy and better bone and renal safety to tenofovir disoproxil fumarate(TDF)in 48 weeks of treatment.Here,we update 96-week comparison results.Methods:Patients with chronic hepatitis B were assigned(2:1)to receive either 25 mg TMF or 300 mg TDF with matching placebo for 96 weeks.The virological suppression was defined as HBV DNA levels<20 IU/mL at week 96.Safety was evaluated thoroughly with focusing on bone,renal,and metabolic pa-rameters.Results:Virological suppression rates at week 96 were similar between TMF and TDF group in both HBeAg-positive and HBeAg-negative populations.Noninferior efficacy was maintained in the pooled population,while it was first achieved in patients with HBV DNA≥7 or 8 log10 IU/mL at baseline.Non-indexed estimated glomerular filtration rate for renal safety assessment was adopted,while a smaller decline of which was seen in the TMF group than in the TDF group(p=0.01).For bone mineral density,patients receiv-ing TMF displayed significantly lower reduction levels in the densities of spine,hip,and femur neck at week 96 than those receiving TDF.In addition,the lipid parameters were stable after week 48 in all groups while weight change still showed the opposite trend.Conclusions:TMF maintained similar efficacy at week 96 compared with TDF with continued superior bone and renal safety profiles(NCT03903796). | Zhihong Liu Qinglong Jin Yuexin Zhang Guozhong Gong Guicheng Wu Lvfeng Yao Xiaofeng Wen Zhiliang Gao Yan Huang Daokun Yang Enqiang Chen Qing Mao Shide Lin Jia Shang Huanyu Gong Lihua Zhong Huafa Yin Fengmei Wang Peng Hu Qiong Wu Chao Pan Wen Jia Chuan Li Chang’an Sun Junqi Niu Jinlin Hou TMF Study Group | 2023 | Journal of Clinical and Translational Hepatology2023，11，3： | 3 |
| 4 | Potential benefit of high-dose intravenous vitamin C for coronavirus disease 2019 pneumonia显示文摘The coronavirus disease 2019(COVID-19)has been declared as a pandemic by the World Health Organization.[1]Most COVID-19 patients exhibit mild to moderate symptoms,while approximately 15%progress rapidly to severe pneumonia,and about 5%eventually develop acute respiratory distress syndrome(ARDS),[2]which requires mechanical ventilation(MV)and even extracorporeal membrane oxygenation.The mortality of COVID-19 patients who received MV was reported to be as high as 66%.[3]Therefore,the treatments aiming to improve mortality should focus on two aspects:first,prevention of the aggravation of the disease in mild and moderate COVID-19 patients;second,the rescue therapy for patients in serious conditions.We have been applying high-dose intravenous vitamin C(HDIVC)in the treatment of critical illnesses for almost 10 years in our center.Our previous in vivo research showed that HDIVC protected hemorrhagic shock-related multiple organ failure(MOF)by inhibiting inflammatory cytokines and oxidative indicators through activating Sirtuin1 pathway. | Bing Zhao Mengjiao Li Yun Ling Yibing Peng Jun Huang Hongping Qu Yuan Gao Yingchuan Li Bijie Hu Shuihua Lu Hongzhou Lu Wenhong Zhang Enqiang Mao | 2022 | Chinese Medical Journal2022，，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员